Safety Monitoring and Who Should Avoid GLP-1 Treatment Patients on insulin or sulfonylureas require dose adjustment and frequent blood glucose monitoring when starting GLP-1 therapy
When this system becomes disrupted, patients may experience symptoms such as abdominal pain, bloating, diarrhea, constipation, urgency, food sensitivity patterns, fatigue, or systemic inflammatory complaints
Metabolic & Hepatic Benefits Tesamorelin improves lipid profiles and reduces liver fat accumulation, supporting metabolic health beyond simple weight reduction
The injection can be given at any time of the day, with or without meals, and should be administered on the same day each week
25 Balance model The Centers for Medicare and Medicaid Services (CMS) also announced the Better Approaches to Lifestyle and Nutrition for Comprehensive Health (BALANCE) model with aims to increase access to selected GLP-1s in Medicaid and Medicare